外分泌膵不全（EPI）治療薬と診断薬の世界市場レポート 2025年

外分泌膵不全（EPI）治療薬と診断薬市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.8％で83億2,000万米ドルに成長します。予測期間の成長は、遠隔医療と遠隔モニタリング、データ分析とai、患者教育とサポート、規制の変更と償還政策に起因しています。予測期間の主な動向には、個別化治療アプローチ、新規治療法の開発、低侵襲診断、共同ケアモデルなどがあります。

糖尿病の有病率の増加は、今後の外分泌膵不全（EPI）治療薬と診断薬市場の拡大を促進すると予測されます。糖尿病は、血糖値の上昇（高血糖）を特徴とする慢性疾患であり、体内でインスリンが十分に分泌されなかったり、インスリンを効果的に使用できなかったりすることが原因です。膵酵素補充療法（PERT）を含むEPI治療は、糖尿病とEPIの両方の患者において、栄養吸収を高め、より良い血糖コントロールをサポートすることができます。例えば、2024年6月、国民保健サービス（NHS England）は、2023年に糖尿病予備軍と診断された人の数が、2022年の3,065,825人から18％増加し、3,615,330人になったと報告しました。40歳未満では、糖尿病予備軍は2022年の173,166人から2023年には216,440人と25％近く増加しました。この糖尿病人口の増加が、EPI治療薬と診断薬の需要を促進しています。

消化器疾患の急増は、当面の外分泌膵不全（EPI）治療薬と診断薬市場の拡大を牽引すると予測されます。消化管疾患には、消化を司る器官を含む消化管に影響を及ぼすさまざまな病状が含まれます。胃腸疾患の管理は、酵素不足を是正し、効果的な栄養消化を促進する外分泌膵不全（EPI）治療薬と診断薬に大きく依存しています。例えば、2023年6月現在、カナダに本部を置く非営利団体Crohn's and Colitis Canadaは、2023年には322,600人以上のカナダ人が炎症性腸疾患（IBD）を患い、人口の約0.82％を占めると推定しています。IBDの有病率は今後も続くと予測され、2035年には約47万人のカナダ人がIBDに罹患すると予想され、これは人口の約1.1％、つまり国民の約91人に1人が罹患することになります。その結果、消化器疾患の罹患率の増加が外分泌膵不全（EPI）治療薬と診断薬市場の成長の原動力になると予想されます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界外分泌膵不全（EPI）治療薬と診断薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の外分泌膵不全（EPI）治療薬と診断薬市場：成長率分析
• 世界の外分泌膵不全（EPI）治療薬と診断薬市場の実績：規模と成長, 2019-2024
• 世界の外分泌膵不全（EPI）治療薬と診断薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界外分泌膵不全（EPI）治療薬と診断薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の外分泌膵不全（EPI）治療薬と診断薬市場治療法別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 栄養管理
• 膵酵素補充療法（PERT）
• ライフスタイル変更アプローチ
• 世界の外分泌膵不全（EPI）治療薬と診断薬市場診断による、実績と予測, 2019-2024, 2024-2029F, 2034F
• 血液検査
• 磁気共鳴画像（MRI）
• 内視鏡的超音波検査（EUS）
• コンピュータ断層撮影（CT）スキャン
• 世界の外分泌膵不全（EPI）治療薬と診断薬市場薬の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ジェネリック
• ブランド
• 世界の外分泌膵不全（EPI）治療薬と診断薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 直接入札
• 小売薬局
• サードパーティディストリビューター
• その他の流通チャネル
• 世界の外分泌膵不全（EPI）治療薬と診断薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• ホームケア
• 診断センター
• 調査・学術機関
• その他のエンドユーザー
• 世界の外分泌膵不全（EPI）治療薬と診断薬市場、栄養管理のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 食生活の変更
• 栄養補助食品
• 世界の外分泌膵不全（EPI）治療薬と診断薬市場膵酵素補充療法（PERT）のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• カプセル製剤
• 錠剤処方
• 粉末製剤
• 世界の外分泌膵不全（EPI）治療薬と診断薬市場、ライフスタイル変更アプローチのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 体重管理
• 身体活動の推奨事項
• 禁煙プログラム

第7章 地域別・国別分析

• 世界の外分泌膵不全（EPI）治療薬と診断薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の外分泌膵不全（EPI）治療薬と診断薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 外分泌膵不全（EPI）治療薬と診断薬市場：競合情勢
• 外分泌膵不全（EPI）治療薬と診断薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Janssen Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Sanofi S.A.
• AstraZeneca plc
• Abott Laboratories
• Medtronic plc
• Solvay S.A.
• Laboratory Corporation of America Holdings（Labcorp）
• Organon group of companies Metagenics LLC
• Allergan plc
• Chiesi Farmaceutici S.p.A.
• Codexis Inc.
• Nordmark Arzneimittel GmbH & Co. KG
• ChiRhoClin Inc.
• Digestive Care Inc.
• Alcresta Therapeutics Inc.
• Vivus Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 外分泌膵不全（EPI）治療薬と診断薬市場2029：新たな機会を提供する国
• 外分泌膵不全（EPI）治療薬と診断薬市場2029：新たな機会を提供するセグメント
• 外分泌膵不全（EPI）治療薬と診断薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics pertain to the treatment of a condition where the pancreas fails to produce adequate digestive enzymes necessary for the effective breakdown and absorption of nutrients from food within the small intestine. The role of EPI diagnostics and therapeutics is pivotal in the identification and management of exocrine pancreatic insufficiency, facilitating individuals with EPI in attaining improved nutrient absorption and overall well-being.

The primary forms of treatments encompassed within exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics comprise nutritional management, pancreatic enzyme replacement therapy (PERT), and lifestyle adjustments. Nutritional management is a specialized healthcare approach utilizing nutrition and diet to address various medical and health conditions. Diverse diagnostic techniques are employed, including blood tests, magnetic resonance imaging (MRI), endoscopic ultrasonography (EUS), and computerized tomography (CT) scanning. Various types of medications, both generic and branded, are utilized, and these are distributed through a range of channels such as direct tender, retail pharmacy, third-party distributor, and others. These are availed by a diverse array of end users including hospitals, specialty clinics, homecare, diagnostic centers, research and academic institutes, among others.

The exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market research report is one of a series of new reports from The Business Research Company that provides exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market statistics, including exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics industry global market size, regional shares, competitors with a exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market share, detailed exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market segments, market trends and opportunities and any further data you may need to thrive in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics industry. This exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market size has grown strongly in recent years. It will grow from $5.69 billion in 2024 to $6.17 billion in 2025 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to increased prevalence of underlying conditions, advancements in diagnostic tools, pharmaceutical developments, rising global healthcare access.

The exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market size is expected to see strong growth in the next few years. It will grow to $8.32 billion in 2029 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to telemedicine and remote monitoring, data analytics and ai, patient education and support, regulatory changes and reimbursement policies. Major trends in the forecast period include personalized treatment approaches, development of novel therapies, minimally invasive diagnostics, collaborative care models.

The growing prevalence of diabetes is anticipated to drive the expansion of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in the future. Diabetes is a chronic condition characterized by elevated blood sugar levels (hyperglycemia), resulting from the body's inability to produce sufficient insulin or use the insulin effectively. EPI treatment, including pancreatic enzyme replacement therapy (PERT), can enhance nutrient absorption and support better glycemic control in individuals with both diabetes and EPI. For example, in June 2024, the National Health Service (NHS England) reported that the number of people diagnosed with pre-diabetes in 2023 increased to 3,615,330, an 18% rise from 3,065,825 in 2022. Among those under 40, pre-diabetes cases rose nearly 25%, from 173,166 in 2022 to 216,440 in 2023. This growing diabetic population is fueling the demand for EPI therapeutics and diagnostics.

The surge in cases of gastrointestinal disorders is projected to drive the expansion of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in the foreseeable future. Gastrointestinal disorders encompass a range of medical conditions affecting the digestive tract, including the organs responsible for digestion. Managing gastrointestinal diseases relies significantly on exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics, which rectify enzyme deficiencies and promote effective nutrient digestion. For instance, as of June 2023, Crohn's and Colitis Canada, a non-profit organization based in Canada, estimated that over 322,600 Canadians were living with inflammatory bowel diseases (IBD) in 2023, constituting about 0.82% of the population. With the prevalence of IBD projected to persist, it is anticipated that approximately 470,000 Canadians will have IBD by 2035, roughly 1.1% of the population, or about 1 in every 91 individuals in the country. Consequently, the escalating incidence of gastrointestinal disorders is anticipated to be a driving force behind the growth of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market.

Key players in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market are increasingly forming strategic partnerships to integrate advanced technologies and broaden their market presence. A strategic partnership involves collaboration between two or more organizations, combining their resources, expertise, and efforts to reach shared objectives. For example, in February 2023, Codexis, Inc., a protein engineering firm based in the US, partnered with Nestle Health Science, a Swiss nutrition company, to announce the interim results of their Phase 1 clinical trial of CDX-7108, an investigational therapy for EPI. These promising results from the trial open the door for further research that could lead to improved treatment options for individuals affected by EPI.

In October 2022, DiaSorin SpA, an Italian biotechnology firm, acquired Luminex Corporation for $1.8 billion. This acquisition allows DiaSorin to bolster its presence in the U.S. market, expand its product portfolio, and establish long-term collaborations with biopharmaceutical companies. Luminex Corporation, based in the U.S., specializes in biological testing technologies, including those related to exocrine pancreatic insufficiency (EPI).

Major companies operating in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market are Pfizer Inc., Merck & Co. Inc., Janssen Pharmaceuticals Inc., AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Abott Laboratories, Medtronic PLC, Solvay S.A., Laboratory Corporation of America Holdings (Labcorp), Organon group of companies Metagenics LLC, Allergan PLC, Chiesi Farmaceutici S.p.A., Codexis Inc., Nordmark Arzneimittel GmbH & Co. KG, ChiRhoClin Inc., Digestive Care Inc., Alcresta Therapeutics Inc., Vivus Inc., Cilian AG, Bioserv Diagnostics Gmbh, Anthera Pharmaceuticals Inc., Aptalis Pharma Inc., First Wave BioPharma Inc., EagleBiosciences Inc., ScheBo Biotech AG.

North America was the largest region in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in 2024. The regions covered in exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market consists of revenues earned by entities by providing dietary interventions and bile acid replacement therapy (BAR). The market value includes the value of related goods sold by the service provider or included within the service offering. The exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market also includes sales of Creon, Zenpep and Ultresa. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for exocrine pancreatic insufficiency (epi) therapeutics and diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Therapies: Nutritional Management; Pancreatic Enzyme Replacement Therapy (PERT); Lifestyle Modifications Approach
• 2) By Diagnostics: Blood Tests; Magnetic Resonance Imaging (MRI); Endoscopic Ultra-Sonography (EUS); Computerized Tomography (CT) Scanning
• 3) By Drug Type: Generic; Branded
• 4) By Distribution Channel: Direct Tender; Retail Pharmacy ; Third-Party Distributor; Other Distribution Channels
• 5) By End User: Hospitals; Specialty Clinics; Homecare; Diagnostic Center; Research And Academic Institutes; Other End Users
• Subsegments:
• 1) By Nutritional Management: Dietary Modifications; Nutritional Supplements
• 2) By Pancreatic Enzyme Replacement Therapy (PERT): Capsule Formulations; Tablet Formulations; Powder Formulations
• 3) By Lifestyle Modifications Approach: Weight Management; Physical Activity Recommendations; Smoking Cessation Programs
• Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; Janssen Pharmaceuticals Inc.; AbbVie Inc.; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Characteristics

3. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Trends And Strategies

4. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Growth Rate Analysis
• 5.4. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Total Addressable Market (TAM)

6. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Segmentation

• 6.1. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nutritional Management
• Pancreatic Enzyme Replacement Therapy (PERT)
• Lifestyle Modifications Approach
• 6.2. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Blood Tests
• Magnetic Resonance Imaging (MRI)
• Endoscopic Ultra-Sonography (EUS)
• Computerized Tomography (CT) Scanning
• 6.3. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Generic
• Branded
• 6.4. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Direct Tender
• Retail Pharmacy
• Third-Party Distributor
• Other Distribution Channels
• 6.5. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Homecare
• Diagnostic Center
• Research And Academic Institutes
• Other End Users
• 6.6. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Sub-Segmentation Of Nutritional Management, BY Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dietary Modifications
• Nutritional Supplement
• 6.7. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Sub-Segmentation Of Pancreatic Enzyme Replacement Therapy (PERT), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Capsule Formulations
• Tablet Formulations
• Powder Formulations
• 6.8. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Sub-Segmentation Of Lifestyle Modifications Approach, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Weight Management
• Physical Activity Recommendations
• Smoking Cessation Programs

7. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Regional And Country Analysis

• 7.1. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

• 8.1. Asia-Pacific Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

• 9.1. China Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
• 9.2. China Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

• 10.1. India Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

• 11.1. Japan Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
• 11.2. Japan Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

• 12.1. Australia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

• 13.1. Indonesia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

• 14.1. South Korea Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
• 14.2. South Korea Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

• 15.1. Western Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
• 15.2. Western Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

• 16.1. UK Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

• 17.1. Germany Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

• 18.1. France Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

• 19.1. Italy Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

• 20.1. Spain Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

• 21.1. Eastern Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
• 21.2. Eastern Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

• 22.1. Russia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

• 23.1. North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
• 23.2. North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

• 24.1. USA Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
• 24.2. USA Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

• 25.1. Canada Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
• 25.2. Canada Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

• 26.1. South America Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
• 26.2. South America Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

• 27.1. Brazil Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

• 28.1. Middle East Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
• 28.2. Middle East Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

• 29.1. Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
• 29.2. Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Competitive Landscape And Company Profiles

• 30.1. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Competitive Landscape
• 30.2. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Janssen Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Other Major And Innovative Companies

• 31.1. Sanofi S.A.
• 31.2. AstraZeneca plc
• 31.3. Abott Laboratories
• 31.4. Medtronic plc
• 31.5. Solvay S.A.
• 31.6. Laboratory Corporation of America Holdings (Labcorp)
• 31.7. Organon group of companies Metagenics LLC
• 31.8. Allergan plc
• 31.9. Chiesi Farmaceutici S.p.A.
• 31.10. Codexis Inc.
• 31.11. Nordmark Arzneimittel GmbH & Co. KG
• 31.12. ChiRhoClin Inc.
• 31.13. Digestive Care Inc.
• 31.14. Alcresta Therapeutics Inc.
• 31.15. Vivus Inc.

32. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

34. Recent Developments In The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

35. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market High Potential Countries, Segments and Strategies

• 35.1 Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer